Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Sofinnova Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
Sofinnova Partners

Sofinnova Partners

Operating

Sofinnova Partners: A Paris-based financial services firm specializing in global startup investments.

Location
Paris, Paris, FR
Founded
1972
Firm
Compare
Portfolio
Fundraising
Employees
News
Website

Sofinnova Partners - Website

An index of every page on sofinnovapartners.com, by section.

19 pages across 6 sections · Updated Jul 16, 2026·

Homepage

Sofinnova Partners's front door: current positioning and top-line messaging.

sofinnovapartners.com

Team

Leadership and the people behind Sofinnova Partners, as the company presents them.

sofinnovapartners.com/team
  • Julia Metzger/team/julia-metzger
  • Hortense Fouilland/team/hortense-fouilland
  • Sylvie Chapoy/team/sylvie-chapoy
  • Artur Mocanu/team/artur-mocanu
  • Simon Turner/team/simon-turner

About

Company story, mission, and background as Sofinnova Partners tells it.

sofinnovapartners.com/about

BlogNews

Product updates, deep-dives, and company thinking: Sofinnova Partners's 6-post archive.

sofinnovapartners.com/news
  • Elicit Plant Validates on a Large Scale the Performance of Its Best a Product for Corn That Reduces Crops Water Consumption and Addresses the Challenges of Climate Change
  • Nuage Therapeutics Appoints Dr Stuart Hughes as CEO and Vanessa Malier as Chair
  • Dna Script Strengthens Its Management Team with the Appointment of Bruno Poddevin as Senior Vice President of Business and Corporate Development
  • Inventiva Strengthens Board of Directors with Appointment of Three Distinguished Life Sciences Leaders
  • Alia Therapeutics Appoints Adel Nada as Independent Board Director

Contact

Sales, support, and partnership channels for reaching Sofinnova Partners directly.

sofinnovapartners.com/contact

ComparisonF2g and Shionogi Announce Positive Topline Results from Global Phase 3 Oasis Study Evaluating Oral Olorofim Versus Ambisome R Followed by Standard of Care in Patients with Invasive Aspergillosis

4 comparison pages published by Sofinnova Partners.

  • F2g and Shionogi Announce Positive Topline Results from Global Phase 3 Oasis Study Evaluating Oral Olorofim Versus Ambisome R Followed by Standard of Care in Patients with Invasive Aspergillosis
  • Gensight Biologics Announces Publication on Matching Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments
  • Micropep Ag Biotech Innovator Raises Eur8 75 Million from Global Syndicate to Bring Ground Breaking and Cost Effective Alternatives to Conventional Crop Protection Products to Market
  • Afyren Secures Over 60 Million Euros of Financing to Move into Its Industrial Development Phase